OSI Pharmaceuticals (OSIP) - formerly Oncogene Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mopgcw who wrote (201)	4/10/2003 12:21:48 PM
From: scaram(o)uche	Read Replies (2) of 447

First, let me say that I'm no fan of Goddard. However!!.... the Genentech trial....... This is a first-line trial, adding the EGFR antagonist to taxol-carboplatin for NSCLC. The trial is fully enrolled, and continues. The trial was designed such that the EGFR antagonist could be continued AFTER a patient had failed first line therapy and/or was subsequently treated with second line chemo or radiation. It is this maintenance therapy which has been stopped, upon observation of the safety signal, by the DSMB. Moreover, the OSIP trials (second and third line therapy, NSCLC and pancreatic) continue as planned.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next